.avif)
.avif)
Horizon Email Format
Biotechnology Research
・
10,001-25,000 employees
・
Thousand Oaks, CA, USA
Horizon is a biotechnology company that discovers, develops, and delivers innovative medicines to treat cancer, heart disease, osteoporosis, inflammatory conditions, and rare diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@horizontherapeutics.com
Company Overview
Industry
Biotechnology Research
Founded
1980
Headquarters
Thousand Oaks, CA, USA
Revenue
$25B-$50B
FUNDING Stage
Public
Website
Key Executives
Robert A. Bradway (Chairman and Chief Executive Officer), Peter Griffith (Executive Vice President and Chief Financial Officer), Esteban Santos (Executive Vice President, Operations)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Horizon?
Horizon uses the firstinitiallast format, so Jane Smith would be jsmith@horizontherapeutics.com.
What rare disease products does Horizon focus on?
Horizon focuses on medicines for rare and severe inflammatory diseases. Its key products include Tepezza for thyroid eye disease, Krystexxa for uncontrolled gout, and Uplizna for neuromyelitis optica spectrum disorder.
How can I find and verify the contact details of a Horizon employee for outreach?
Since Horizon uses the firstinitiallast format at horizontherapeutics.com, you can build a likely email address for any contact you have. Tools like Clay can help you verify those addresses and enrich your prospect list with additional details before reaching out.
Where is Horizon headquartered and what is its relationship to Amgen?
Horizon is based in Deerfield, Illinois, and operates as a subsidiary of Amgen following Amgen's $27.8 billion acquisition that closed in October 2023. The business continues to run under the Horizon Therapeutics name within Amgen's rare disease portfolio.
Did Horizon Therapeutics advance its subcutaneous Tepezza program in 2026?
Yes, in April 2026, Amgen announced positive topline Phase 3 results for a subcutaneous version of Tepezza, showing a 77% proptosis response rate versus 19.6% for placebo in adults with moderate-to-severe active thyroid eye disease.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating